NCT02001727

Brief Summary

Aims:

  1. 1.Evaluate the long-term effect of screening and eradication of Helicobacter Pylori on the prevalence of dyspepsia, and, as secondary outcomes, to assess the effect on dyspepsia related health-care consumption and quality of life.
  2. 2.To investigate symptoms of gastroesophageal reflux (GER), dyspepsia and the combination of these conditions and the effect on quality of life, prognosis and dyspepsia-related health care expenditure.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10,000

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2012

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2012

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

September 16, 2013

Completed
3 months until next milestone

First Posted

Study publicly available on registry

December 5, 2013

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2015

Completed
Last Updated

November 20, 2014

Status Verified

November 1, 2014

Enrollment Period

2.9 years

First QC Date

September 16, 2013

Last Update Submit

November 19, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • Economic Evaluation

    The overall endpoint is expenditure in Danish kroner (on ulcer drugs, upper gastrointestinal endoscopy, GP consultations, hospital admissions related to peptic ulcer). Data on resource consumption of these services and procedures is multiplied with relevant unit prices, from the Danish Medicines Agency and the Danish National Board of Health, to assess a health-cost endpoint.

    twelve years

Secondary Outcomes (6)

  • Frequency of symptoms (dyspepsia, reflux)

    twelve years

  • Drug consumption

    Twelve years

  • Quality of life

    twelve years

  • Incidence of esophagus- and gastric cancer

    Twelve years

  • Upper gastrointestinal endoscopy / X-ray examinations of esophagus and gastric ventricle.

    Twelve Years

  • +1 more secondary outcomes

Study Arms (2)

Hp-screened group

ACTIVE COMPARATOR

Screened for Helicobacter Pylori and eradication therapy (1998-99)

Other: Questionaire

Control group

OTHER

primarily unscreened group

Other: 13C-Urea breath test for Helicobacter PyloriOther: Questionaire

Interventions

Control groupHp-screened group

Eligibility Criteria

Age52 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Individuals participating in 5 year follow-up

You may not qualify if:

  • Individuals not participating in 5 year follow-up
  • Moved outside the Region of Southern Denmark or with an unknown address
  • Individuals who died

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Bomme M, Hansen JM, Wildner-Christensen M, Hallas J, Schaffalitzky de Muckadell OB. Effects of Community Screening for Helicobacter pylori: 13-Year Follow-Up Evaluation of a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2017 Nov;15(11):1715-1723.e7. doi: 10.1016/j.cgh.2017.06.006. Epub 2017 Jun 9.

MeSH Terms

Conditions

Peptic UlcerDyspepsiaGastroesophageal Reflux

Condition Hierarchy (Ancestors)

Duodenal DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesStomach DiseasesSigns and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and SymptomsEsophageal Motility DisordersDeglutition DisordersEsophageal Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

September 16, 2013

First Posted

December 5, 2013

Study Start

March 1, 2012

Primary Completion

February 1, 2015

Study Completion

February 1, 2015

Last Updated

November 20, 2014

Record last verified: 2014-11